Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Low-risk prostate cancer patients will benefit from active surveillance guidelines

Wellington campus

Wednesday 15 October 2014 11:17am

Professors Brett Delahunt and John Nacey
Professor Brett Delahunt (left) and Professor John Nacey.

New guidelines for active surveillance of prostate cancer will improve health outcomes for those with low grade diagnoses, according to two University of Otago, Wellington (UOW) experts who had input in to the international recommendations.

Prostate cancer is the most commonly diagnosed cancer in New Zealand men aged 45 and over, with around 2,500 diagnosed annually. Treatment options include surgery or radiation, or patients might be suitable for active surveillance – whereby they don't receive treatment but are closely monitored for changes in their cancer.

UOW pathologist Professor Brett Delahunt and urologist Professor John Nacey were part of an international, multi-specialty team convened by the College of American Pathologists that has highlighted pathologic parameters that are key for the successful identification of patients likely to benefit from active surveillance.

The team’s recommendations have been published in the October issue of the highly-prestigious Archives of Pathology and Laboratory Medicine.

Active surveillance is an important management option for men with low-risk prostate cancer, particularly as removal of the prostate carries the small risk of impotence or incontinence, Professor Delahunt says.
The new guidelines provide, for the first time, clear pathologic parameters for identifying those most likely to benefit from active surveillance and avoid such risks, he says.

“To date there has been no consensus on now to determine eligibility for active surveillance. These new protocols will allow us to better determine who is appropriate for active surveillance and when it should be stopped and the patient moved on to treatment.”

For further information contact:

Professor Brett Delahunt
Department of Pathology and Molecular Medicine
University of Otago, Wellington
Tel: 64 4 385 5569

A list of Otago experts available for media comment is available elsewhere on this website.

Electronic addresses (including email accounts, instant messaging services, or telephone accounts) published on this page are for the sole purpose of contact with the individuals concerned, in their capacity as officers, employees or students of the University of Otago, or their respective organisation. Publication of any such electronic address is not to be taken as consent to receive unsolicited commercial electronic messages by the address holder.